fleroxacin has been researched along with Bacterial Disease in 18 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The object of this open-label, randomized, comparative study was to evaluate the efficacy and safety of fleroxacin versus conventional therapy (cefazolin plus gentamicin/cephalexin) in the treatment of patients with bacterial liver abscess." | 9.10 | A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. ( Chen, YS; Chen, YW; Huang, WK; Lee, SS; Lin, HH; Liu, YC; Wann, SR; Yen, MY, 2002) |
| "In a multicenter study the efficacy and safety of oral fleroxacin at 400 mg once a day and amoxicillin at 500 mg three times daily for 7 days were compared for the treatment of patients with acute bacterial exacerbations of chronic bronchitis due to drug-susceptible bacteria." | 9.07 | Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. ( Chodosh, S, 1993) |
| "This study was designed to test the efficacy of 400 mg fleroxacin given orally as a single dose or once daily for 3 days against acute bacterial diarrhea." | 9.07 | Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days. ( Butler, T; del Rosal, PL; Iskandar, H; Kadio, A; Lolekha, S; Pastore, G; Rasidi, C; Rubinstein, E, 1993) |
| "In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration." | 9.07 | [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991) |
| "To assess the potential efficacy of fleroxacin in combination with clindamycin or metronidazole in mixed aerobic and anaerobic infections, we used a rat model of intra-abdominal abscesses in which the inoculum consisted of pooled rat feces mixed with BaSO4." | 7.69 | Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses. ( Eliopoulos, GM; Ferraro, MJ; Holden, J; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C, 1994) |
| "The object of this open-label, randomized, comparative study was to evaluate the efficacy and safety of fleroxacin versus conventional therapy (cefazolin plus gentamicin/cephalexin) in the treatment of patients with bacterial liver abscess." | 5.10 | A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. ( Chen, YS; Chen, YW; Huang, WK; Lee, SS; Lin, HH; Liu, YC; Wann, SR; Yen, MY, 2002) |
| "In a multicenter study the efficacy and safety of oral fleroxacin at 400 mg once a day and amoxicillin at 500 mg three times daily for 7 days were compared for the treatment of patients with acute bacterial exacerbations of chronic bronchitis due to drug-susceptible bacteria." | 5.07 | Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. ( Chodosh, S, 1993) |
| "This study was designed to test the efficacy of 400 mg fleroxacin given orally as a single dose or once daily for 3 days against acute bacterial diarrhea." | 5.07 | Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days. ( Butler, T; del Rosal, PL; Iskandar, H; Kadio, A; Lolekha, S; Pastore, G; Rasidi, C; Rubinstein, E, 1993) |
| "In this study, fleroxacin (FLRX), a new quinolone derivative, was orally given at 300 mg once daily for 14 days to 102 patients with non-catheterized complicated urinary tract infections in order to determine the optimal treatment duration." | 5.07 | [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin]. ( Arakawa, S; Hamami, G; Hazama, M; Kamidono, S; Matsumoto, O; Okamoto, Y; Sengoku, A; Takagi, S; Tanaka, H; Yamazaki, H, 1991) |
| "To assess the potential efficacy of fleroxacin in combination with clindamycin or metronidazole in mixed aerobic and anaerobic infections, we used a rat model of intra-abdominal abscesses in which the inoculum consisted of pooled rat feces mixed with BaSO4." | 3.69 | Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses. ( Eliopoulos, GM; Ferraro, MJ; Holden, J; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C, 1994) |
| "Fleroxacin was given at a dosage of 400 mg once daily, and AMX/CP was given at a dosage of 500 mg/125 mg three times a day." | 2.67 | Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue. ( Powers, RD, 1993) |
| " Clinical adverse events related to the trial medication were reported by 40 (21%) of 189 patients in the fleroxacin group and by 16 (17%) of 95 patients in the AMX/CP group." | 2.67 | Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. ( Tassler, H, 1993) |
| "Fleroxacin has a relatively long elimination half-life, which allows once-daily administration, and it appears to have less propensity for interactions with other medications in comparison to many other fluoroquinolones." | 2.39 | Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. ( Balfour, JA; Peters, DH; Todd, PA, 1995) |
| "Fleroxacin is a new member of the class of fluoroquinolones." | 2.38 | Fleroxacin clinical pharmacokinetics. ( Frey, FJ; Kim, DK; Stuck, AE, 1992) |
| "Fleroxacin was inactive against S." | 1.28 | In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. ( Beskid, G; Chan, K; Cleeland, R; Keith, DD; McGarry, CM; Siebelist, J, 1990) |
| "Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus, Enterobacter species, Escherichia coli, Klebsiella species, Proteus vulgaris, and Serratia marcescens (inhibiting greater than 90% of these isolates at a concentration of 0." | 1.28 | In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. ( Bodey, GP; Ho, DH; LeBlanc, B; Messer, M; Nguyen, H; Rolston, KV, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 15 (83.33) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albrecht, HA | 1 |
| Beskid, G | 2 |
| Christenson, JG | 1 |
| Durkin, JW | 1 |
| Fallat, V | 1 |
| Georgopapadakou, NH | 1 |
| Keith, DD | 2 |
| Konzelmann, FM | 1 |
| Lipschitz, ER | 1 |
| McGarry, DH | 1 |
| Remuzon, P | 1 |
| Bouzard, D | 1 |
| Cesare, PD | 1 |
| Essiz, M | 1 |
| Jacquet, JP | 1 |
| Kiechel, JR | 1 |
| Ledoussal, B | 1 |
| Kessler, RE | 1 |
| Fung-Tomc, J | 1 |
| Chen, YW | 1 |
| Chen, YS | 1 |
| Lee, SS | 1 |
| Yen, MY | 1 |
| Wann, SR | 1 |
| Lin, HH | 1 |
| Huang, WK | 1 |
| Liu, YC | 1 |
| Kosmidis, J | 1 |
| Gargalianos, P | 1 |
| Lelekis, M | 1 |
| Adamis, G | 1 |
| Petropoulou, D | 1 |
| Makris, D | 1 |
| Balfour, JA | 1 |
| Todd, PA | 1 |
| Peters, DH | 1 |
| Pefanis, A | 1 |
| Thauvin-Eliopoulos, C | 1 |
| Holden, J | 1 |
| Eliopoulos, GM | 1 |
| Ferraro, MJ | 1 |
| Moellering, RC | 1 |
| Chodosh, S | 1 |
| Smith, JW | 1 |
| Nichols, RL | 1 |
| Powers, RD | 1 |
| Tassler, H | 1 |
| Butler, T | 1 |
| Lolekha, S | 1 |
| Rasidi, C | 1 |
| Kadio, A | 1 |
| del Rosal, PL | 1 |
| Iskandar, H | 1 |
| Rubinstein, E | 1 |
| Pastore, G | 1 |
| Stuck, AE | 1 |
| Kim, DK | 1 |
| Frey, FJ | 1 |
| Arakawa, S | 1 |
| Takagi, S | 1 |
| Matsumoto, O | 1 |
| Kamidono, S | 1 |
| Sengoku, A | 1 |
| Hazama, M | 1 |
| Yamazaki, H | 1 |
| Hamami, G | 1 |
| Okamoto, Y | 1 |
| Tanaka, H | 1 |
| Matsuda, S | 1 |
| Shimizu, T | 1 |
| Cho, N | 1 |
| Satoh, K | 1 |
| Minaguchi, H | 1 |
| Yagami, Y | 1 |
| Okada, H | 1 |
| Hirabayashi, K | 1 |
| Deguchi, K | 1 |
| Siebelist, J | 1 |
| McGarry, CM | 1 |
| Cleeland, R | 1 |
| Chan, K | 1 |
| Rolston, KV | 1 |
| Nguyen, H | 1 |
| Messer, M | 1 |
| LeBlanc, B | 1 |
| Ho, DH | 1 |
| Bodey, GP | 1 |
| Gu, JW | 1 |
| Neu, HC | 1 |
| Hirai, K | 1 |
| Aoyama, H | 1 |
| Hosaka, M | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study[NCT00895089] | Phase 4 | 24 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fleroxacin and Bacterial Disease
| Article | Year |
|---|---|
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Topics: Animals; Bacteria; Bacterial Infections; Clinical Trials as Topic; Drug Interactions; Fleroxacin; Hu | 1995 |
Fleroxacin clinical pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Drug Interactions; Female; Fleroxacin; Gram-Ne | 1992 |
7 trials available for fleroxacin and Bacterial Disease
| Article | Year |
|---|---|
A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial I | 2002 |
Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Confi | 1993 |
Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combin | 1993 |
Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue.
Topics: Administration, Oral; Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; | 1993 |
Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium | 1993 |
Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Diarrhea; Double-Blin | 1993 |
[A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, | 1991 |
9 other studies available for fleroxacin and Bacterial Disease
| Article | Year |
|---|---|
Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.
Topics: Animals; Bacterial Infections; Cephalosporins; Chemical Phenomena; Chemistry; Mice; Microbial Sensit | 1991 |
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Dogs; Indicators and R | 1991 |
Acute, uncomplicated, lower urinary tract infections: the role of single-dose fleroxacin.
Topics: Adolescent; Adult; Age Factors; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topi | 1989 |
Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.
Topics: Abdomen; Abscess; Animals; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Clindamycin | 1994 |
[Clinical evaluation of fleroxacin in gynecological infections].
Topics: Administration, Oral; Adolescent; Adult; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluat | 1991 |
In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Drug Evaluation, Pr | 1990 |
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fleroxacin; Fluoroquinolones; | 1990 |
In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bacterial Infections; Cefotaxime; Ciprofloxa | 1990 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |